Breast Cancer
ImmunoGen announces presentation of first clinical data on Genentech's Trastuzumab-MCC-DM1
Published in Genetics and Environmental Health Week, January 17th, 2007
Trastuzumab-MCC-DM1 is being developed by Genentech and uses ImmunoGen's Tumor-Activated Prodrug (TAP) technology.
The compound comprises Genentech's trastuzumab anti-HER2 antibody and ImmunoGen's DM1 cell-killing agent. ImmunoGen's TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells.
"We're delighted with the clinical findings with trastuzumab-MCC-DM1 being...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Health Week
More Articles from Genetics and Environmental Health Week
- Antisocial Behavior
Studies from Harvard University provide new data on antisocial behavior in children - Asthma Genetics
New findings reported from University of Cincinnati, Division of Immunology describe advances in asthma genetics - Atherosclerosis Genetics
Scientists at Hadassah University describe research in atherosclerosis genetics - Autoimmune Disease Genetics
Research from University of Sao Paulo, Department of Genetics in the area of autoimmune disease genetics published - Bipolar Disorders Genetics
Researchers from Vrije University publish new studies and findings in the area of bipolar disorders genetics - Breast Cancer Genetics
Reports on breast cancer genetics findings from University of Western Ontario provide new insights - More from this issue of Genetics and Environmental Health Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
